Luteinizing hormone is produced by the pituitary gland as part of the normal hormonal cycle that governs ovulation in women and testosterone production in men. HCG, by contrast, is produced by placental tissue during pregnancy and has no natural role in the non-pregnant body at all.
Despite coming from entirely different sources, both hormones converge on the same cellular target, a receptor called LHCGR, found on cells in the ovaries and testes. This shared receptor is the entire reason hCG has any clinical relevance outside of pregnancy.
HCG and LH belong to the same family of glycoprotein hormones and share a nearly identical beta subunit region in the part of the molecule responsible for receptor binding. That structural overlap is close enough that the LHCGR receptor cannot meaningfully distinguish between the two hormones and responds to either one in essentially the same way.
This relationship is a specific example of the broader alpha and beta subunit structure shared across the glycoprotein hormone family, discussed in more detail in our dedicated article on hCG subunits.
The clinically important difference is not what the two hormones do at the receptor, but how long they last in the bloodstream. LH is cleared from circulation quickly, within a matter of hours, while hCG persists for a much longer period thanks to its heavier glycosylation.
That longer half-life is precisely why hCG, not LH itself, is the molecule used in clinical settings where a sustained hormonal signal is useful, such as triggering final oocyte maturation in fertility treatment or maintaining testicular stimulation in male hypogonadism therapy.
It is a useful illustration of a broader principle in endocrine pharmacology: a molecule does not need to be structurally identical to a natural hormone to substitute for it clinically, it only needs to activate the same receptor with a pharmacokinetic profile that suits the intended treatment goal.
In fertility medicine, this LH-mimicking property is why hCG is used as part of ovulation induction protocols, discussed further in our article on hCG in IVF cycles. In men, the same mechanism underlies its use in restoring testicular testosterone production, covered in our article on hCG and male fertility.
In both cases, hCG is not acting as a novel drug with its own independent mechanism; it is essentially standing in for a hormone the body already knows how to use, which is part of why its clinical profile is so well understood.
None of this receptor-sharing relationship makes hCG interchangeable with LH for self-directed or unsupervised use. Both hormones require careful clinical dosing decisions made by a physician based on individual hormone panels, and hCG remains a prescription-only pharmaceutical in the UAE regardless of the biology involved.